Company Filing History:
Years Active: 1999-2001
Title: Soledad Valera: Innovator in Receptor Technology
Introduction
Soledad Valera is a prominent inventor based in Geneva, Switzerland. She has made significant contributions to the field of receptor technology, particularly in the development of methods for screening compounds that bind to the P2X receptor. With a total of 2 patents, her work has implications for various medical conditions.
Latest Patents
One of her latest patents is a method of screening for compounds that bind to the P2X receptor. This receptor, which is crucial for ATP signaling, has been cloned and expressed using recombinant DNA technology. The ability to prepare the P2X receptor free from other ATP receptors allows for the development of antibodies and is instrumental in screening compounds for a range of diseases and conditions. These include epilepsy, cognitive disorders, emesis, pain management (especially migraines), asthma, peripheral vascular disease, hypertension, immune system diseases, irritable bowel syndrome, and premature ejaculation.
Career Highlights
Soledad Valera is currently employed at Glaxo Group Limited, where she continues to advance her research and innovations. Her work is characterized by a commitment to improving therapeutic options for patients suffering from various ailments.
Collaborations
Soledad collaborates with Gary N Buell, leveraging their combined expertise to further their research initiatives.
Conclusion
Soledad Valera's contributions to receptor technology and her innovative patents highlight her role as a leading inventor in the field. Her work not only advances scientific understanding but also has the potential to improve treatment options for numerous health conditions.